Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L, et al.
2023-05-22 • Lancet HIV
2023-05-22 • Lancet HIV
BACKGROUND The drug-drug interaction between rifampicin and dolutegravir can be overcome by supplemental dolutegravir dosing, which is difficult to implement in high-burden settings....
“We were hungry all the time”, is the first thing a 28-year-old tuberculosis survivor from rural Haiti told one of us (JF) when asked in 2017 about his experience of being treated for th...
Cornell M, Johnson LF, Schomaker M, Tanser F, Maskew M, et al.
2015-08-03 • Lancet HIV
2015-08-03 • Lancet HIV
BACKGROUND As access to antiretroviral therapy (ART) expands, increasing numbers of older patients will start treatment and need specialised long-term care. However, the effect of ag...
Vika began to tremble uncontrollably as the car her family spent their entire savings on approached the hospital. Although she willed herself to stop, her emaciated frame shook with the ...
Dhana A, Hamada Y, Kengne AP, Kerkhoff AD, Rangaka MX, et al.
2022-04-01 • Lancet HIV
2022-04-01 • Lancet HIV
BACKGROUND Since 2011, WHO has recommended that HIV-positive inpatients be routinely screened for tuberculosis with the WHO four-symptom screen (W4SS) and, if screened positive, rece...
Ford NP, Patten GE, Rangaraj A, Davies MA, Meintjes GA, et al.
2022-03-01 • Lancet HIV
2022-03-01 • Lancet HIV
BACKGROUND The identification and appropriate management of people with advanced HIV disease is a key component in the HIV response. People with HIV who are hospitalised are at a hig...
Schramm B, Temfack E, Descamps D, Nicholas S, Peytavin G, et al.
2022-08-01 • Lancet HIV
2022-08-01 • Lancet HIV
BACKGROUND Many countries are now replacing non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line antiretroviral therapy (ART) with a regimen containing tenofovir d...
